TNDM

+ Watchlist + Portfolio

Tandem Diabetes Care, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.46
52-Week Range: $10.44 – $29.65
Market Cap: $1.57B
P/E (TTM): —
EPS (TTM): -0.90
Dividend Yield: —

Advanced Metrics

Price/Book: 12.04
PEG Ratio: —
Return on Equity: -48.03%
Return on Assets: -2.65%
Gross Margin: 56.01%
Operating Margin: -5.42%
Profit Margin: -6.08%
Current Ratio: 3.18
Debt/Equity: 5.67
Total Debt: $739.25M
Free Cash Flow: $-43.95M
Revenue Growth: 5.80%
Earnings Growth: —
Enterprise Value: $1.92B

TNDM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$801.22M	$747.72M	$940.20M	$1.01B
Cost of Revenue	$388.23M	$380.03M	$450.63M	$468.72M
Gross Profit	$412.99M	$367.69M	$489.57M	$546.01M
Research & Development	$170.15M	$248.42M	$198.88M	$268.33M
Selling, General & Admin	$335.68M	$352.50M	$389.82M	$444.99M
Operating Expenses	$505.83M	$600.92M	$588.70M	$713.32M
Operating Income	-$92.85M	-$233.23M	-$99.13M	-$167.31M
EBITDA	-$74.21M	-$196.46M	-$69.75M	-$176.56M
Pretax Income	-$92.85M	-$220.25M	-$91.87M	-$200.27M
Income Tax	$1.74M	$2.36M	$4.16M	$4.44M
Net Income	-$94.59M	-$222.61M	-$96.03M	-$204.71M
Diluted EPS	-1.47	-3.43	-1.47	-3.04
Diluted Shares	64.15M	64.97M	65.45M	67.28M

TNDM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$172.52M	$58.87M	$69.23M	$90.63M
Receivables	$114.72M	$105.56M	$114.58M	$165.49M
Inventory	$111.12M	$157.94M	$149.61M	$128.77M
Current Assets	$849.98M	$747.99M	$724.49M	$618.14M
Total Assets	$1.05B	$952.66M	$967.66M	$881.11M
Current Liabilities	$165.29M	$195.26M	$247.05M	$242.72M
Long-Term Debt	$283.23M	$285.04M	$308.27M	$310.04M
Total Debt	$419.88M	$415.67M	$473.56M	$444.48M
Total Liabilities	$612.84M	$639.03M	$704.56M	$725.94M
Retained Earnings	-$729.19M	-$951.80M	-$1.05B	-$1.25B
Shareholders' Equity	$439.95M	$313.63M	$263.10M	$155.17M
Working Capital	$684.69M	$552.73M	$477.44M	$375.42M
Net Debt	$110.72M	$226.17M	$279.70M	$219.40M

TNDM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$50.46M	-$31.81M	$24.23M	-$9.72M
Capital Expenditure	-$34.10M	-$96.30M	-$19.23M	-$98.54M
Free Cash Flow	$16.37M	-$128.11M	$4.99M	-$108.26M
Depreciation & Amortisation	$14.33M	$15.71M	$16.61M	$17.67M
Stock-Based Compensation	$84.92M	$88.08M	$101.38M	$92.38M
Investing Cash Flow	$33.17M	-$85.74M	-$23.48M	$72.88M
Financing Cash Flow	$16.88M	$4.11M	$8.37M	-$43.37M
Net Change in Cash	$100.51M	-$113.44M	$9.11M	$19.79M

TNDM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$234.42M	$240.68M	$249.25M	$290.38M	$247.22M
Cost of Revenue	$116.02M	$114.82M	$114.96M	$122.92M	$110.43M
Gross Profit	$118.41M	$125.86M	$134.29M	$167.46M	$136.79M
Research & Development	$125.43M	$48.12M	$48.72M	$46.07M	$46.03M
Selling, General & Admin	$113.85M	$109.60M	$108.44M	$113.10M	$108.19M
Operating Expenses	$239.28M	$157.71M	$157.16M	$159.17M	$154.22M
Operating Income	-$120.88M	-$31.86M	-$22.86M	$8.29M	-$17.43M
EBITDA	-$116.42M	-$50.82M	-$18.59M	$9.39M	-$13.74M
Pretax Income	-$122.09M	-$57.72M	-$25.14M	$4.68M	-$19.88M
Income Tax	$8.47M	-$5.32M	-$3.98M	$5.27M	$516.00K
Net Income	-$130.56M	-$52.40M	-$21.16M	-$589.00K	-$20.39M
Diluted EPS	-1.97	-0.78	-0.31	-0.01	-0.30
Diluted Shares	66.40M	67.05M	67.65M	68.01M	68.40M

TNDM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$53.57M	$64.11M	$91.95M	$90.63M	$179.32M
Receivables	$126.56M	$128.44M	$125.94M	$165.49M	$140.67M
Inventory	$141.16M	$142.57M	$137.28M	$128.77M	$126.40M
Current Assets	$663.43M	$614.82M	$616.94M	$618.14M	$887.10M
Total Assets	$922.14M	$875.74M	$874.65M	$881.11M	$1.15B
Current Liabilities	$288.18M	$251.69M	$252.54M	$242.72M	$247.96M
Long-Term Debt	$308.70M	$309.15M	$309.59M	$310.04M	$601.77M
Total Debt	$493.20M	$449.01M	$449.28M	$444.48M	$734.74M
Total Liabilities	$766.85M	$742.45M	$741.69M	$725.94M	$1.02B
Retained Earnings	-$1.18B	-$1.23B	-$1.25B	-$1.25B	-$1.27B
Shareholders' Equity	$155.29M	$133.28M	$132.97M	$155.17M	$132.40M
Working Capital	$375.26M	$363.13M	$364.40M	$375.42M	$639.14M
Net Debt	$295.87M	$245.03M	$217.64M	$219.40M	$422.44M

TNDM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$18.28M	-$9.50M	$8.26M	$9.79M	$11.05M
Capital Expenditure	-$46.43M	-$6.21M	-$4.09M	-$41.81M	-$6.27M
Free Cash Flow	-$64.71M	-$15.70M	$4.17M	-$32.02M	$4.79M
Depreciation & Amortisation	$4.31M	$4.37M	$4.49M	$4.50M	$4.50M
Stock-Based Compensation	$25.49M	$25.64M	$21.14M	$20.11M	$15.66M
Investing Cash Flow	$9.19M	$58.13M	$20.54M	-$14.98M	-$195.45M
Financing Cash Flow	-$4.69M	-$39.71M	-$1.57M	$2.60M	$274.16M
Net Change in Cash	-$13.78M	$8.92M	$27.23M	-$2.58M	$89.77M

Market Snapshot

About

Tandem Diabetes Care is a medical device company focused on developing and commercializing insulin delivery systems for people with diabetes. The company is best known for its t:slim X2 insulin pump with Control-IQ technology, which features automated insulin delivery and continuous glucose monitoring integration. Tandem offers innovative solutions designed to simplify diabetes management and improve patient outcomes.